small molecule

CARDAMYST

ETRIPAMIL

Loss of exclusivityJuly 2042latest FDA-listed patent expiry

CompanyMilestone Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	CARDAMYST
Active ingredient	ETRIPAMIL
Strength	70MG
Dosage form	SPRAY
Route	NASAL
Modality	Small molecule
FDA approval	December 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
12257224	July 2042	use U-4370
10117848	April 2036	product
10010522	June 2028	use U-38
9463179	June 2028	use U-4370
10010523	June 2028	substance
9227918	June 2028	product

Regulatory exclusivity

Code	Expires
NCE	December 2030

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.